1. Home
  2. ARVN vs OMDA Comparison

ARVN vs OMDA Comparison

Compare ARVN & OMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.95

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

OMDA

Omada Health Inc.

HOLD

Current Price

$17.97

Market Cap

978.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARVN
OMDA
Founded
2015
2011
Country
United States
United States
Employees
N/A
943
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Nursing Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
658.2M
978.5M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ARVN
OMDA
Price
$8.95
$17.97
Analyst Decision
Buy
Buy
Analyst Count
19
11
Target Price
$15.05
$21.73
AVG Volume (30 Days)
858.9K
1.2M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
58.84
N/A
EPS
N/A
N/A
Revenue
$262,600,000.00
N/A
Revenue This Year
N/A
$24.96
Revenue Next Year
N/A
$20.08
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.06
$10.28
52 Week High
$14.22
$26.92

Technical Indicators

Market Signals
Indicator
ARVN
OMDA
Relative Strength Index (RSI) 37.05 70.80
Support Level $8.72 $14.39
Resistance Level $10.18 $19.26
Average True Range (ATR) 0.47 0.86
MACD 0.00 0.09
Stochastic Oscillator 28.82 84.64

Price Performance

Historical Comparison
ARVN
OMDA

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About OMDA Omada Health Inc.

Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.

Share on Social Networks: